In Dravet syndrome, as well as in other SCN1A-related seizure disorders, sodium channel blockers such as carbamazepine, lamotrigine, phenytoin are contraindicated as they may increase frequency and severity of seizures (Catterall, 2014; Miller and Sotero de Menezes, 2014; Schoonjans et al., 2015). This evidence concerns the gene SCN1A and encephalopathy, progressive, early-onset, with brain edema and/or leukoencephalopathy.